OBJECTIVES:  Proton pump inhibitors (PPIs) are the most effective antisecretory drugs in the treatment of acid-related diseases of digestive organs. METHODS:  Assessment of PPI consumption was carried out by ATC/DDD-methodology. International Number of PPIs packaging, which were sold for a year in Ukraine, was taken from the information system "Drugs" of Company "Morion" (August, 2011-2015.). PPIs DDD are taken from the WHO website (http://www.whocc.no/atc_ddd_index/). The data «Baltic Statistics on Medicines 2010-2012» was used to assess PPIs consumption in the Baltic countries (Lithuania, Latvia, Estonia), the data «Drug Consumption in Norway 2009-2013» - in Norway. RESULTS:  Volumes of PPIs consumption in terms of DDDs/1000 inhabitants/day increased in 1,4 times in Ukraine during 2011-2015: from 5.99 in 2011 to 8.24 in 2015. From 2011 to 2015 in Ukraine the volumes of consumption increased for omeprazole (in 1.4 times), pantoprazole (in 2 times), ezomeprazole (in 5 times), decreased - for rabeprazole (in 3 times) and lansoprazole (in 2 times). According to the volume of PPIs consumption in 2011-2012 countries studied can be positioned the following order: Norway > Estonia > Latvia > Lithuania > Ukraine. In Ukraine, the PPIs were consumed 3 times was less than in the Baltic countries, 6.5 times less - than in Norway. Drugs of omeprazole, pantoprazole, lansoprazole, esomeprazole were presented in Ukraine, in the Baltic countries and Norway, rabeprazole - only in Ukraine and Lithuania. Omeprazole - the leader by consumption volumes among PPIs in Ukraine and the Baltic countries, esomeprazole - in Norway. CONCLUSIONS:  Approximately from 0.59 to 0.82 % of the Ukraine population every day took 1 DDD of one of PPIs in 2011-2015. Level of PPIs consumption in terms of DDDs /1000 inhabitants/day in Ukraine was less than the level of PPIs consumption in the Baltic countries and Norway in 2011-2012.